<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00145925</url>
  </required_header>
  <id_info>
    <org_study_id>ADVANCE</org_study_id>
    <nct_id>NCT00145925</nct_id>
  </id_info>
  <brief_title>Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes</brief_title>
  <official_title>ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The George Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut de Recherches Internationales Servier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sydney</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The George Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide information on the risks and benefits of routine&#xD;
      blood pressure lowering (regardless of blood pressure level), and intensive lowering of blood&#xD;
      glucose levels, in patients with Type 2 diabetes at high risk of cardiovascular events. The&#xD;
      major outcomes of the study will be cardiovascular events (heart attack, stroke or dying as a&#xD;
      result of cardiovascular disease), as well as new or worsening diabetic eye and kidney&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with type 2 diabetes are at increased risks of macrovascular and microvascular&#xD;
      disease, both of which are reduced by control of raised blood pressure in hypertensive&#xD;
      individuals. Intensive glycaemic control has also been shown to reduce microvascular disease,&#xD;
      but the effects on macrovascular disease remain uncertain. This study will examine the&#xD;
      hypotheses that blood pressure lowering (with an ACE inhibitor-diuretic combination) and&#xD;
      intensive glycaemic control (with a sulphonylurea-based regimen) in high-risk individuals&#xD;
      with type 2 diabetes (including hypertensive and non-hypertensive subjects) reduces the&#xD;
      incidence of both macrovascular and microvascular disease.&#xD;
&#xD;
      The study is a 2 x 2 factorial randomised controlled trial that includes 11,140 adults with&#xD;
      type 2 diabetes at elevated risk of vascular disease. Following 6 weeks on open label&#xD;
      perindopril-indapamide combination, eligible individuals were randomised to continued&#xD;
      perindopril-indapamide or matching placebo, and to an intensive gliclazide MR-based glucose&#xD;
      control regimen (aiming for HbA1c of 6.5% or lower) or usual guidelines-based therapy.&#xD;
      Primary outcomes are, first, the composite of non-fatal stroke, non-fatal myocardial&#xD;
      infarction or cardiovascular death and, second, the composite of new or worsening nephropathy&#xD;
      or diabetic eye disease. These primary outcomes will be analysed jointly and separately. The&#xD;
      average duration of treatment and follow-up is 5.5 to 6 years. The study is being conducted&#xD;
      in 214 centres in Australasia, Asia, Europe and North America.&#xD;
&#xD;
      ADVANCE is designed to provide reliable evidence about the balance of benefits and risks&#xD;
      conferred by blood pressure lowering therapy and intensive glucose control therapy in&#xD;
      high-risk diabetic patients, irrespective of initial blood pressure or glucose levels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2001</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of non-fatal stroke, non-fatal myocardial infarction or death from any cardiovascular cause</measure>
    <time_frame>July 2001 - December 2007</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of new or substantially worsening nephropathy or microvascular eye disease.</measure>
    <time_frame>July 2001 - December 2007</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Includes cerebrovascular disease, coronary heart disease, heart failure, peripheral vascular disease, cardiovascular and all-cause mortality, microalbuminuria, visual deterioration, new or worsening nephropathy, cognitive function, and dementia.</measure>
    <time_frame>July 2001 - December 2007</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11140</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Blood pressure</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Perindopril indapamide vs placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucose control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard versus intensive glucose control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perindopril-indapamide</intervention_name>
    <arm_group_label>Blood pressure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gliclazide MR-based glucose lowering</intervention_name>
    <arm_group_label>Glucose control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A diagnosis of type 2 diabetes mellitus first made at age 30 years or older&#xD;
&#xD;
          2. Age 55 years or older at entry&#xD;
&#xD;
          3. Ability to provide informed consent&#xD;
&#xD;
          4. A substantially elevated risk of cardiovascular disease, indicated by:&#xD;
&#xD;
               -  A history of major macrovascular disease defined as any one of: stroke,&#xD;
                  myocardial infarction, hospital admission for transient ischaemic attack,&#xD;
                  hospital admission for unstable angina, coronary artery bypass graft,&#xD;
                  percutaneous transluminal coronary angioplasty (with or without stenting),&#xD;
                  peripheral revascularisation (angioplasty or surgery) or amputation secondary to&#xD;
                  vascular disease or&#xD;
&#xD;
               -  A history of major microvascular disease defined as any one of nephropathy&#xD;
                  (albumin:creatinine ratio &gt;300ug/mg), retinal photocoagulation therapy,&#xD;
                  proliferative retinopathy (new blood vessels on the disc or elsewhere, vitreous&#xD;
                  haemorrhage, pre-retinal haemorrhage, or fibrous proliferations on the disc or&#xD;
                  elsewhere), macular oedema (retinal thickening within one disc diameter of the&#xD;
                  macular centre) or blindness in either eye (corrected visual acuity 6/60 or&#xD;
                  worse, persisting for three months or more) not known to be due to non-diabetic&#xD;
                  causes or&#xD;
&#xD;
               -  A first diagnosis of type 2 diabetes made 10 or more years prior to entry or&#xD;
&#xD;
               -  Another major risk factor for vascular disease defined as any one of: current&#xD;
                  daily cigarette smoking, total cholesterol greater than 6.0 mmol/l (with or&#xD;
                  without cholesterol lowering treatment), HDL cholesterol &lt;1.0 mmol/l,&#xD;
                  microalbuminuria (albumin:creatinine ratio 30-300ug/mg) or&#xD;
&#xD;
               -  Age 65 years or over&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A definite contraindication to treatment with an ACE inhibitor or a thiazide-like&#xD;
             diuretic&#xD;
&#xD;
          2. A specific indication for treatment with an ACE inhibitor other than perindopril 2-4&#xD;
             mg daily (see also section 5.2.3) or a thiazide-like diuretic&#xD;
&#xD;
          3. A definite and specific indication for treatment with gliclazide or a haemoglobin A1c&#xD;
             control target of 6.5% or less&#xD;
&#xD;
          4. A definite contra-indication to treatment with gliclazide or a haemoglobin A1c control&#xD;
             target of 6.5% or less&#xD;
&#xD;
          5. A definite indication for long-term full-dose or bed-time insulin therapy&#xD;
&#xD;
          6. Participation in a trial within the month prior to the Registration Visit or current&#xD;
             participation in another trial&#xD;
&#xD;
        Other potential reasons for ineligibility include:&#xD;
&#xD;
          -  High probability of non-adherence to study treatment or follow-up&#xD;
&#xD;
          -  Current clinical instability (e.g. a major cerebral or coronary event or&#xD;
             sight-threatening retinopathy or macular oedema within the previous few weeks)&#xD;
&#xD;
          -  Life threatening non-vascular disease other than diabetes and its complications&#xD;
&#xD;
          -  Moderate or severe dementia&#xD;
&#xD;
          -  Major disability that is likely to prevent regular attendance at study clinics&#xD;
&#xD;
        Final decisions about eligibility were made at the discretion of the study investigator and&#xD;
        the potential study participant, in the light of any requirements or guidance from local&#xD;
        ethics committees and other regulatory bodies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Chalmers, MB BS PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The George Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen W MacMahon, BSc PhD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>The George Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Melbourne</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H26 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute &amp; Fu Wai Hospital</name>
      <address>
        <city>Xicheng District</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Julius Center for Health Sciences and Primary Care</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 BA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College School of Medicine</name>
      <address>
        <city>London</city>
        <zip>W2 1PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>China</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.thegeorgeinstitute.org/</url>
    <description>Sponsor's web page</description>
  </link>
  <reference>
    <citation>Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation. J Hypertens Suppl. 2001 Nov;19(4):S21-8.</citation>
    <PMID>11848259</PMID>
  </reference>
  <reference>
    <citation>ADVANCE Collaborative Group (Writing Committee - J Chalmers, S Colman, S Heller, S MacMahon, B Neal, C Pan, A Patel, M Woodward). ADVANCE - Action in Diabetes and Vascular Disease: characteristics of participants at baseline. Diabetic Medicine 2005;22:882-888.</citation>
  </reference>
  <reference>
    <citation>ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation. Diabetologia. 2001 Sep;44(9):1118-20.</citation>
    <PMID>11596665</PMID>
  </reference>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>September 2, 2005</study_first_submitted>
  <study_first_submitted_qc>September 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2005</study_first_posted>
  <last_update_submitted>September 16, 2008</last_update_submitted>
  <last_update_submitted_qc>September 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2008</last_update_posted>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <keyword>Blood Pressure</keyword>
  <keyword>Stroke</keyword>
  <keyword>MI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gliclazide</mesh_term>
    <mesh_term>Perindopril</mesh_term>
    <mesh_term>Indapamide</mesh_term>
    <mesh_term>Indapamide, perindopril drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

